Table 1.

Bacterial strains and plasmids

Strain or plasmidRelevant properties and commentsaSource or reference(s)
Strains
E. coli
  DH5α recA endA1 gyrA96 thi-1 hsdR17 supE44 relA1 φ80 lacZΔM15 Bethesda Research Laboratories
  SN01 ampA1+ ampC+pyrB thr leu recA rpsL 25
  SN03 ampA1 ampC8 pyrB thr leu recA rpsL; spontanous SN01 mutant (mutations in structural and regulatory regions of ampC) 25
  K-12 XACNar Rir 41
  TKH11 E. coli XAC transformant from plasmid preparation of KH11 42
  TNBL63 E. coli XAC transformant from plasmid preparation of NBL63 42
K. oxytoca
  KH11Azr Xmr clinical isolate 41, 42
  KH55AzrXmr clinical isolate 41, 42
  KH78Azr Xmr clinical isolate 41, 42
  KH93AzrXmr clinical isolate 41, 42
  NBL63Azr Xmr clinical isolate 41, 42
Plasmids
 pGEM-3ZAmpr subcloning vectorPromega
 pNU6Ampr harboringampC 10
 pKH11Plasmid fromK. oxytoca KH11 (subgroup 2) 41, 42
 pNBL63Plasmid from K. oxytoca NBL63 (subgroup 3) 41, 42
 pTKH11Plasmid from transformant TKH11 42
 pTKH78Plasmid from transformant TKH78 42
 pTNBL63Plasmid from transformant TNBL63 42
 pSW-21pGEM-3Z with 0.85-kbPstI fragment of pTKH11This study
 pSW-22pGEM-3Z with 2.74-kb PstI-BglII fragment of pTKH11This study
 pSW-24pGEM-3Z with 2.24-kbBglII fragment of pTKH11This study
 pSW-28pGEM-3Z with 5.96-kb BglII fragment of pTKH11This study
 pSW-26pGEM-3Z with 2.45-kbBglII fragment of pNBL63This study
  • a Amp, ampicillin; Az, aztreonam; Na, nalidixic acid; Ri, rifampin; Xm, cefuroxime.